SHERIDAN, WYOMING – May 7, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), a leading medical technology company, has announced the appointment of Patrick Daly as its new Chief Business Officer. Daly, a seasoned veteran with over 30 years of experience in the healthcare industry, will play a crucial role in driving business growth and enhancing Terumo BCT's strategic initiatives.
With a distinguished career in business development and strategic partnerships, Daly brings valuable expertise to the company as it continues to expand its portfolio of solutions for blood collection, therapeutic apheresis, and cell therapy. His leadership is expected to accelerate Terumo BCT's goals for innovation, market integration, and enterprise expansion.
A Proven Leader with Global Expertise
Patrick Daly's professional journey spans multiple senior leadership roles, with notable achievements in driving both organic and inorganic growth strategies across various global markets. Before joining Terumo BCT, Daly played an instrumental role in establishing and growing the MedTech Global Data franchise at IQVIA, a prominent provider of technology solutions to the life sciences industry. His experience with capital acquisition, strategic partnerships, and data monetization aligns perfectly with Terumo BCT’s long-term vision for growth.
Prior to his tenure at IQVIA, Daly served as the President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. His extensive career at Johnson & Johnson further complements his strong foundation in strategic marketing, sales, and business development. Daly earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point, demonstrating his dedication to leadership and problem-solving on a global scale.
Accelerating Innovation and Business Integration
Daly's appointment is seen as a strategic move to unite Terumo BCT’s diverse business units and enhance its go-to-market strategies. According to Antoinette Gawin, President and CEO of Terumo BCT, "Patrick's experience acquiring capital and building strategic partnerships complements his expertise in monetizing data and solutions. This uniquely positions him to integrate our offerings and drive innovation across our business models."
Daly himself is enthusiastic about the company's future, saying, “It is a great moment to join Terumo BCT as it continues executing its long-term vision for growth and to meet patients’ unmet needs globally. I am focused on ensuring our full portfolio, connected with data, software, and services, will play a growing role in helping our customers solve healthcare's toughest challenges.”
Terumo BCT’s Strategic Focus
Terumo BCT is at the forefront of medical technology, delivering solutions that empower customers to collect and prepare blood and cells for critical therapeutic applications. The company’s portfolio supports a variety of healthcare providers, including blood centers, hospitals, apheresis clinics, and private medical practices in over 150 countries.
With more than 750 granted patents and over 150 pending, Terumo BCT is committed to advancing research, therapeutic development, and improving patient access to safe blood worldwide. Its global presence is supported by multiple regional headquarters, manufacturing sites, and innovation centers.
As Terumo BCT continues to innovate and expand, the company remains focused on driving growth through strategic leadership and collaborations, ensuring that its products and services play a key role in tackling healthcare's most pressing challenges.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies, a subsidiary of Terumo Corporation, specializes in medical technology solutions that enhance the collection and processing of blood and cells. Its products, software, and services are essential in addressing complex diseases and conditions, making significant contributions to the healthcare sector. With a robust global presence, Terumo BCT is committed to providing innovative, reliable solutions that support both patient care and medical research.